Abbreviations: HCT-CI = hematopoietic cell transplant-comorbidity index; MDS = myelodysplastic syndromes; PB = peripheral blood.
Allogeneic hematopoietic SCT (allo-HSCT) is an effective treatment for haematological malignancies. As only about 30% of patients have a matched sibling donor or matched unrelated donor, transplantation from a related haploidentical donor is an effective option. 1 There are several kinds of protocols for haploidential transplantation. In our institution, we have developed a novel haploidentical transplantation protocol that does not require in vitro T-cell depletion. With the modified BU-CY conditioning regimen, patients receiving unmanipulated haploidentical SCT (haplo-HSCT) can achieve favourable outcomes. 1 However, our previous reports demonstrate that patients with comorbidities have high TRM and low OS while receiving the conventional BU-CY regimen. 2, 3 Much of the observed regimenrelated toxicities, such as the cardiac toxicity, veno-occlusive disease and haemorrhagic cystitis, are due to CY. 4 Substitution with Fludarabine (Flu) is associated with a low incidence of TRM. 5, 6 Our previous reports demonstrate that, in older patients and/or patients with severe comorbidities, a modified BU/Flu regimen is well tolerated and safe for use with HLA-identical sibling transplantation. 7, 8 The outcomes of a CY-containing regimen and a Flu-containing regimen have never been compared in the unmanipulated haploidentical transplantation setting. The purpose of this study was to understand the impact of substituting CY with Flu on the outcomes of unmanipulated haploidentical HSCT for haematologic malignancies in older patients or in patients with comorbidities.
From 2008 to 2013, 17 patients received unmanipulated haplo-HSCT with a Flu-based regimen in the Peking University Institute of Hematology for the following reasons: (1) age of 55-60 years (7 patients); (2) blood creatinine42.0 mg/dL within 2 weeks before the start of conditioning (3 patients); (3) previous autologous HSCT in the last 4 months (2 patients); (4) corrected pulmonary diffusion capacity between 50 and 52% (2 patients); (5) bundle branch block and cardiac ejection fraction of 52% associated with chemotherapy (2 patients); and (6) disseminated intravascular coagulation associated with refractory acute promyelocytic leukaemia (1 patient). These 17 patients were categorized as the BU-Flu group.
From 2006 to 2008, 386 patients received unmanipulated haplo-HSCT with a CY-based regimen. Among the 148 consecutive patients with a hematopoietic SCT comorbidity index (HCT-CI) 9 ⩾ 3, 68 patients (in a 4:1 ratio) were randomly selected as the control group (BU-CY group).
The characteristics of the 85 patients are summarised in Table 1 . The study protocol was approved by the ethics committee at Peking University People's Hospital. Informed consent was provided according to the Declaration of Helsinki. was substituted with Flu (30 mg/m 2 /day, injected i.v.) from day-6 to day-2. All transplant recipients received CsA, mycophenolate mofetil and short-term MTX for GVHD prophylaxis as previously described. 1 The underlying disease was classified as high risk or standard risk. High-risk diseases included acute leukaemia in nonremission or in the third or greater CR, acute leukaemia with the translocation t(9;22), and CML in the blast phase; standard-risk disease included all other diagnoses.
A relapse was defined as the reappearance of blasts in the blood or BM (45%) or in any extramedullary site after a CR. TRM was defined as any cause of death other than relapse. Leukaemiafree survival (LFS) was defined as survival with continuing CR. The last follow-up was carried out on 31 July 2014.
A total of five patients developed primary graft failure, three in the BU-Flu group and two in the BU-CY group (Supplementary Table 1 ). The cumulative incidence of primary engraftment failure was higher in the BU-Flu group than in the BU-CY group (17.6% versus 3.0%, P = 0.04). However, in the multivariate analysis (Supplementary Table 2 ), no factors were associated with a high incidence of graft failure. In the BU-Flu group, the median time of neutrophil engraftment and platelet engraftment was 15 (9-21) and 23 (8-40) days respectively. In the BU-CY group, the median time of neutrophil engraftment and platelet engraftment was 14 (10-27) and 19 ) days, respectively.
There was no difference in the 100-day CIs of grade 3-4 GHVD between the two groups (28.3% in BU-CY versus 16.4% in BU-Flu, P = 0.37). Chronic GVHD was evaluated in those patients who survived 4100 days after transplantation. The 2-year CI of chronic GVHD was 41.6% in the BU-Flu group and 41.3% in the BU-CY group (P = 0.26).
The TRM in the BU-Flu group on day 20 and day 100 and at 1 year and 2 years was 0%, 29.4%, 41.2% and 49.0%, respectively. The TRM in the BU-CY group on day 20 and day 100 and at 1 year and 2 years was 1.4%, 14.9%, 29.8% and 32.9%, respectively.
The 2-year TRM did not differ significantly between the two groups (P = 0.28) (Figure 1a) . In the multivariate analysis, no factor was associated with a high TRM (Supplementary Table 2 ).
The 2-year CI of relapse (CIR) did not differ between the two groups (14.4 and 27.5%, P = 0.69) (Figure 1b) . High-risk disease before transplantation was the only factor associated with a higher CIR (hazard ratio = 4.624; 95% confidence interval, 1.387-15.417; P = 0.013) (Supplementary Table 2) .
At the last follow-up, 7 patients (41.2%) in the BU-Flu group and 32 (47.0%) in the BU-CY group were alive. The 2-year probability of OS was 39.2% in the BU-Flu group and 50.7% in the BU-CY group (P = 0.15; Figure 1c) . The 2-year LFS was 39.0% in the BU-Flu group and 46.2% in the BU-CY group (P = 0.44; Figure 1d ).
To our knowledge, no such comparison between CY and Flu has been made for elderly patients or for patients with comorbidities that have undergone haploidentical transplantation. Our study indicated that BU-CY and BU-Flu lead to similar outcomes in the specific setting.
Although is seems that Flu is less lymphoablative than CY, 10 BU-Flu was not associated with higher graft failure rate in multivariate analysis. And owing to the less organ damage, some retrospective studies demonstrated that Flu is associated with decreased TRM and improved OS and LFS. However, this superiority of Flu has not been demonstrated in prospective randomized studies. [11] [12] [13] In our study, TRM was comparable in two groups. It suggests that BU-Flu may be feasible in this special group of patients who have elder age or with comorbidities.
One concern is that reduced organ damage by the Bu-Flu regimen might cause a lower antileukaemic effect or a higher relapse rate than the BU-CY regimen. In the present study, no difference in the relapse rate was observed between the two regimens and other studies using the BU-Flu regimen also reported similar relapse rates. 6, 14 Previous studies demonstrated that nucleoside analogues combined with alkylating agents exert synergistic antitumour effects by inhibiting repair from alkylatorinduced DNA damage. Therefore, we believe that fludarabine combined with BU may have sufficient antitumour effect. The present study is limited by its retrospective nature: there may be some selection bias. Patients with good performance status may be prone to be assigned to BU-CY group, whereas patients with poor performance would receive the BU-Flu regimen more commonly. Although we have performed a multivariable analysis for compensating for such differences, it is important to take note of this limitation of the study. In addition, only 18 patients with Bu-Flu have been treated, the small sample size may have impact on the solidity of results. Also, Flu and BU were not optimally given which may be an important factor associated with outcome, while regarding that the sequential use of fludarabine followed by BU is important. 15 In conclusion, this study revealed that the substitution of CY with fludarabine in a BU-based regimen might be feasible in patients with unmanipulated haploidentical HSCT. However, prospective studies were needed to further investigate optimal conditioning regimens for patients of older age and with comorbidities.
